Multidrug-resistant Acinetobacter baumannii infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation-Reference-Cited by-同舟云学术

Multidrug-resistant Acinetobacter baumannii infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation

Published:2019-06 Issue:6 Volume:53 Page:726-745
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Mohd Sazlly Lim Sazlyna,Sime Fekade Bruck^ORCID,Roberts Jason A.^ORCID

Funder

National Health and Medical Research Council

University of Queensland

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference191 articles.

1. Acinetobacter baumannii: emergence of a successful pathogen;Peleg;Clin Microbiol Rev,2008

2. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms;Neidell;Clin Infect Dis,2012

3. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii;Lautenbach;Infect Control Hosp Epidemiol,2009

4. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections;Karageorgopoulos;Lancet Infect Dis,2008

5. A multicenter case–case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia;Ng;Infect Control Hosp Epidemiol,2014

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature;Journal of Antimicrobial Chemotherapy;2024-08-31

2. The HOG‐pathway related AaOS1 leads to dicarboximide‐resistance in field strains of Alternaria alternata and contributes, together with the Aafhk1, to mycotoxin production and virulence;Pest Management Science;2024-02-28

3. Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens;2024 Nelson’s Pediatric Antimicrobial Therapy;2024-02-12

4. Combination eravacycline therapy for ventilator‐associated pneumonia due to carbapenem‐resistant Acinetobacter baumannii in patients with COVID‐19: A case series;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-01-25

5. Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens;2023 Nelson’s Pediatric Antimicrobial Therapy;2023-03-01